Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

Inclusion Criteria: * Age above 18 and under 80 years of age, both gender, in good health. * Clinical diagnosis of retinitis pigmentosa, the results of eye electrophysiological examination accord with retinitis pigmentosa. * The BCVA of target eye will not be better than 20/400. * The BCVA of contralateral eye is not worse than 20/400. * Diopter is smaller than 8.00 D, axial 28 mm or less. * Voluntary as test subjects, signed informed consent, regular follow-up will be effected according to the specified time. Exclusion Criteria: * Subject with other additional retinal diseases, like diabetic or hypertensive retinopathy vascular diseases. * Target eye ever have had a eye surgery; * Subject with active serious diseases of the digestive system, liver kidney impairment (ALT/AST) \> 1.5 or any known liver disease, creatine \> 1.3 mg/dL) and/serious temic diseases, such as cardiovascular tem, respiratory tem, nervous tem, endocrine tem urogenital tem diseases, etc.), the history of malignancy; * Have been ready for pregnancy during test, are lactating women; * Ready to birth of men during the test; * Subject with any immunodeficiency; * Subject in the immunosuppressive therapy in the current; * Subject with the tacrolimus or other large ring lactone class drug allergies; * Participate in any clinical subjects in nearly six months; * Has a history of alcohol or illicit drug abuse; * Poor adherence to complete studies; * Researchers believe that there may be an increased risk subjects or interfere with the clinical trials of any situation (such as when a patient is prone to mental tension, depression, mental illness, cognitive dysfunction, etc.).